Cytokinetics INC Form 4 insider transactions

Cytokinetics EVP of Research & Development, Fady Ibraham Malik, reported transactions involving the acquisition and sale of common stock and stock options.

Cytokinetics President and CEO Robert I. Blum filed a Form 4 indicating a planned sale of 7,500 common shares on April 1, 2026, under a Rule 10b5-1 plan.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, reported the sale of 3,639 common shares at $65 per share, executed under a pre-arranged 10b5-1 trading plan.

Cytokinetics' EVP and CFO, Sung Lee, sold 4,935 shares of common stock at $62.15 per share to cover tax withholding obligations related to RSU vesting.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, sold 8,542 shares of common stock to cover tax withholding obligations from RSU vesting.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, sold 12,033 shares of common stock to satisfy tax withholding obligations from RSU vesting.

Cytokinetics' President & CEO, Robert I. Blum, sold shares to cover tax withholding obligations from RSU vesting.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, sold 1,930 shares of common stock for $62.07 per share in a pre-planned transaction.

Cytokinetics' President and CEO, Robert I. Blum, received annual equity awards including restricted stock units and stock options.

Cytokinetics' EVP and Chief Commercial Officer, Andrew Callos, was granted significant equity awards, including restricted stock units and stock options, effective March 15, 2026.

Cytokinetics' Chief Legal & Admin Officer, Jeffrey Hessekiel, was granted significant equity awards including restricted stock units and stock options on March 15, 2026.

CYTOKINETICS' EVP of Research & Development, Fady Ibraham Malik, received significant equity awards including restricted stock units and stock options.

Cytokinetics EVP Andrew Callos sold 1,709 shares of common stock for $61.03 per share under a pre-arranged trading plan.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, exercised stock options and subsequently sold a portion of his common stock holdings on March 5, 2026.

Cytokinetics Director B. Lynne Parshall sold 5,000 shares of common stock at $61.21 per share in a pre-planned transaction.

Cytokinetics' Chief Commercial Officer, Andrew Callos, exercised stock options and simultaneously sold an equal number of shares under a pre-arranged 10b5-1 plan.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, exercised stock options and subsequently sold an equal number of shares under a pre-arranged plan.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, exercised stock options and subsequently sold an equal number of shares in a pre-planned transaction.

Cytokinetics Director James M. Daly acquired 197 shares of common stock at $63.44 per share, opting for equity in lieu of a cash retainer.

Cytokinetics Director Nancy Wysenski acquired 98 shares of common stock at $63.44 per share, increasing her direct beneficial ownership to 30,971 shares.

Cytokinetics Director Wendell Wierenga acquired 98 shares of common stock at $63.44 per share as part of an equity compensation plan.

Cytokinetics Director Edward M. Kaye MD acquired 197 shares of common stock at $63.44 per share as part of an equity compensation plan.

Cytokinetics Director John T. Henderson acquired 334 shares of common stock at $63.44 per share as equity compensation.

Cytokinetics director Robert Arthur Harrington acquired 197 shares of common stock at $63.44 per share on January 15, 2026, as part of an equity compensation plan.

Cytokinetics' EVP, Chief Commercial Officer Andrew Callos, exercised stock options and subsequently sold an equal number of common shares, as per a Rule 10b5-1 plan.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, reported future planned sales of common stock following option exercises under a 10b5-1 plan.

Cytokinetics' EVP, Chief Commercial Officer Andrew Callos, sold 1,809 shares of common stock for $62.44 per share under a Rule 10b5-1 plan.

Cytokinetics CEO Robert I. Blum increased his beneficial ownership through performance share awards, partially offset by tax-related share withholding.

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, increased his direct beneficial ownership of common stock through performance share awards.

Cytokinetics' Chief Commercial Officer, Andrew Callos, reported the acquisition of performance shares and a tax-related disposition, resulting in a net increase in his direct beneficial ownership.